Efficacy and Safety of Fremanezumab for Episodic Cluster Headache

Study Title

A Study to Evaluate the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Episodic Cluster Headache (ECH)

Teva Identifier

TV48125-CNS-30056 | 2016-003278-42

ClinicalTrials.gov Identifier

NCT02945046

Study Status

Terminated

Trial Condition(s)

Episodic Cluster Headache

Interventions

Drug: Fremanezumab | Drug: Placebo

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
ClinicalTrials.gov study records with inclusion and exclusion criteria

Key Participation Requirements

Gender

Female, Male

Age Range

18 Years to 70 Years

Trial Duration

January 19, 2017 - May 13, 2019

Phase

Phase 3

Additional info

Study Type

Interventional